X4 Pharmaceuticals (XFOR) Scheduled to Post Quarterly Earnings on Wednesday

X4 Pharmaceuticals (NASDAQ:XFOR) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $3.43 million during the quarter. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Up 7.4 %

Shares of NASDAQ:XFOR opened at $0.66 on Tuesday. The firm has a 50 day simple moving average of $0.60 and a 200 day simple moving average of $0.76. X4 Pharmaceuticals has a 52 week low of $0.47 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07. The company has a market cap of $111.75 million, a PE ratio of 8.29 and a beta of 0.39.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $126,854.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now directly owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 580,800 shares of company stock valued at $321,447 in the last three months. 1.62% of the stock is currently owned by company insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.